Results

1–7 of 7 results for anti-vascular endothelial growth factor

Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Intravitreal Therapeutics Utilization in 2023
Anton M Kolomeyer, MD, PhD
Annual Meeting Talks
2024
Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis
Dan A Gong, MD
Annual Meeting Talks
2022
Cognitive Testing in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration
Subhransu K. Ray, MD, PhD
Annual Meeting Talks
2020
Current Practice Preferences and Antisepsis Protocols for Intravitreal Anti-vascular Endothelial Growth Factor Injections
David Xu, MD
On Demand Cases, Courses, and Papers
2019
Visual Acuity Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Vein Occlusion in Routine Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2019